TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03821129: GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

Sponsor: W.L.Gore & Associates · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 636 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,924,000

Rescue Site Savings

+$5,897,600

Unlock Full NCT03821129 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03821129 Rescue Dossier →